RATIONALE 304: Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for non-squamous non-small cell lung cancer in patients who are smokers vs non-smokers

Shun Lu*,¹ Dingzhi Huang,² Xueqin Chen,³ Baocheng Wang,⁴ Jianxin Xue,⁵ Jie Wang,⁶ Yuanyuan Bao,⁷ Liang Liang,⁷ Xiusong Qiu,⁷ Weisheng Chen⁷

Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jao Tong University, Shanghai, China; ⁴Utanjin Medical University General Hospital, Tianjin, China; ⁴Department of Medical Oncology, Hangzhou First People's Hospital, Hangzhou Center Hospital, Hangzhou China; ⁴Chinese Academy of Sciences, Beijing, China; ⁴Vest China School of Medicine, West China Hospital, Sichuan University, Chengdu, China; ⁴State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; ⁴State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical College, Beijing, China; ⁴Beidene (Shanghai) Co., Ltd., Beijing, China;

Poster No. 3786

Introduction and methods

- B Smoking is the leading risk factor for developing lung cancer in adults, with the risk of lung cancer increasing by up to 30-fold in smokers compared to non-smokers^{1,2}
- Tiselizumab is a humanized immunoglobulin G4 monoclonal antibody with high affinity and binding specificity for programmed death protein 1 (PD-1)^{3.4}
- Primary results from the RATIONALE 304 study showed that the addition of tislelizumab to chemotherapy resulted in significantly improved progression-free survival (PFS) and a consistent safety and tolerability profile compared with chemotherapy alone in the first-line treatment of advanced non-sequamous non-small cell lung cancer (non-sq NSCLO)⁵
- Bere, we report the results of a sub-analysis of patients who were smokers or non-smokers from the Phase 3 RATIONALE 304 study
- Methods have been described previously⁵

Scan QR code to view the primary publication of RATIONALE 304:

Results

Patients

- $_{\rm B}$ Between July 2018 and July 2019, 334 patients aged 25–75 years were randomized 2:1 to either Arm A (n=223) or Arm B (n=111)^5
- The median age was 61.0 years and 247 (74.0%) patients were male⁵
- In total, 213 (63.8%) patients were smokers and 121 (36.2%) were non-smokers (Table 1)

Table 1. Demographics and baseline characteristics in patients who were smokers or non-smokers (ITT analysis set)

	Smc	kers	Non-smokers			
	Arm A TIS + PP (n=147)	Arm B PP (n=66)	Arm A TIS + PP (n=76)	Arm B PP (n=45)		
Age (years)						
Median (min-max)	61.0 (27-75)	63.0 (25-74)	58.0 (32-75)	59.0 (40-74)		
Sex, n (%)						
Male	147 (100.0)	64 (97.0)	21 (27.6)	15 (33.3)		
ECOG PS, n (%)						
0	38 (25.9)	15 (22.7)	16 (21.1)	9 (20.0)		
1	109 (74.1)	51 (77.3)	60 (78.9)	36 (80.0)		
Smoking status, n (%)						
Never	0 (0.0)	0 (0.0)	76 (100.0)	45 (100.0)		
Current	32 (21.8)	13 (19.7)	0 (0.0)	0 (0.0)		
Former	115 (78.2)	53 (80.3)	0 (0.0)	0 (0.0)		
Solid tumor stage, n (%)						
IIIB	26 (17.7)	13 (19.7)	14 (18.4)	8 (17.8)		
IV	121 (82.3)	53 (80.3)	62 (81.6)	37 (82.2)		
TC PD-L1 expression, n (%)						
< 1%	72 (49.0)	24 (36.4)	24 (31.6)	24 (53.3)		
1-49%	32 (21.8)	15 (22.7)	21 (27.6)	12 (26.7)		
> 50%	43 (29.3)	27 (40.9)	31 (40.8)	9 (20.0)		

Conclusions

 In this sub-analysis, observed improvements in PFS and ORR suggest treatment benefits of tislelizumab plus chemotherapy in patients with advanced non-sq NSCLC

- The efficacy and safety results of tislelizumab plus chemotherapy in patients who were smokers with advanced non-sq NSCLC were consistent with the overall population of this Phase 3 RATIONALE 304 study⁵
- a As of data cut-off on January 23, 2020, 117 patients (35.0%) remained on treatment, of whom 75 (35.2%) patients were smokers and 42 (34.7%) patients were non-smokers
 - The most common reasons for discontinuation for patients who were smokers were radiographic progression (43.7%) and adverse events (9.4%). The most common reasons for discontinuation for patients who were non-smokers were radiographic progression (40.5%) and patient withdrawal of consent (14.0%)

Efficacy

- In patients who were smokers, PFS by independent review committee (IRC) was longer in Arm A compared with Arm B (Figure 1A)
- Median PFS was 9.7 months in Arm A and 4.6 months in Arm B (HR: 0.466 [95% CI: 0.311, 0.697])
- $_{\mbox{\tiny D}}$ In patients who were non-smokers, PFS by the IRC was similar between the two arms (Figure 1B)
- Median PFS was 8.5 months in Arm A and 7.7 months in Arm B (HR: 1.075 [95% CI: 0.596, 1.940])
- $_{\odot}$ The objective response rate (ORR) and median duration of response (DoR) for patients who were smokers or non-smokers are shown in Table 2
- Regardless of smoking status, the ORR was higher with tislelizumab plus chemotherapy (Arm A) vs chemotherapy alone (Arm B)




Figure 1. PFS by IRC in patients who were: A) Smokers (Arm A vs Arm B) or

Table 2. Disease response and DoR by IRC in patients who were smokers or non-smokers (ITT analysis set)

	Smol	kers	Non-smokers			
	Arm A Arm B TIS + PP PP (n=147) (n=86)		Arm A TIS + PP (n=76)	Arm B PP (n=45)		
ORR, % (95% CI)	61.2 (52.8, 69.1)	31.8 (20.9, 44.4)	50.0 (38.3, 61.7)	44.4 (29.6, 60.0		
Complete response, n (%)	5 (3.4)	0 (0.0)	2 (2.6)	1 (2.2)		
Partial response, n (%)	85 (57.8)	21 (31.8)	36 (47.4)	19 (42.2)		
Median DoR, months (95% CI)	8.5 (6.34, NE)	8.5 (5.98, NE)	7.4 (4.96, NE)	5.4 (4.44, NE)		
HR, (95% CI)	0.938 (0.3	39, 2.262)	0.788 (0.354, 1.752)			

Data cut-off, January 23, 2020: CI, confidence interval; DoR, duration of response; HR, hazard ratio: HC, independent review committee; ITT, intention-to-treat; NE, not estimable; ORR, objective response rate; PP, pemetrexed + platinum; TIS, listelizumab

Safety

- The safety profile of tislelizumab plus chemotherapy and chemotherapy alone in patients who were smokers or non-smokers is outlined in Table 3
- The safety profile in patients who were smokers or non-smokers was consistent with the overall patient population⁵
- Regardless of smoking status, most patients (97.7%–100.0%) experienced ≥ 1 treatment-emergent adverse event (TEAE)

 Of the patients who were smokers, 67.8% and 54.5% of patients experienced ≥ 3 Grade TEAEs in Arms A and B, respectively
 Of the patients who were non-smokers. 67.1% and 52.3% experienced

≥ 3 Grade TEAEs in Arms A and B, respectively

 $_{\rm D}$ In patients who were smokers, five (3.4%) patients in Arm A and two (3.0%) patients in Arm B reported a TEAE leading to death. Two TEAEs leading to death in Arm A were reported to be related to tislelizumab treatment (Table 3)

- In patients who were non-smokers, two (2.6%) patients in Arm A and no (0.0%) patients in Arm B reported a TEAE leading to death. One TEAE leading to death in Arm A was reported to be related to tislelizumab treatment (Table 3)
- □ Treatment-related adverse events (TRAEs) occurring in ≥ 20% of patients in any treatment group are listed in Table 4

 The most common immune-mediated TEAE occurring in patients who were smokers or non-smokers was pneumonitis (11.0%) and hypothyroidism (10.5%), respectively

Table 3. Overall summary of TEAEs and TRAEs in patients who were smokers or non-smokers (safety analysis set)

	Smol	kers	Non-sr	nokers
	Arm A TIS + PP (n=146)	Arm B PP (n=66)	Arm A TIS + PP (n=76)	Arm B PP (n=44)
Patients with ≥ 1 TEAE	146 (100.0)	66 (100.0)	76 (100.0)	43 (97.7)
≥ Grade 3	99 (67.8)	36 (54.5)	51 (67.1)	23 (52.3)
Serious	52 (35.6)	15 (22.7)	22 (28.9)	8 (18.2)
≥ Grade 3 serious	39 (26.7)	12 (18.2)	15 (19.7)	3 (6.8)
Leading to treatment discontinuation	39 (26.7)	6 (9.1)	18 (23.7)	4 (9.1)
Leading to death	5 (3.4)	2 (3.0)	2 (2.6)	0 (0.0)
Patients with ≥1 TRAE	145 (99.3)	64 (97.0)	76 (100.0)	43 (97.7)
≥ Grade 3	90 (61.6)	30 (45.5)	50 (65.8)	20 (45.5)
Serious	34 (23.3)	9 (13.6)	15 (19.7)	6 (13.6)
Leading to death	2 (1.4)	1 (1.5)	1 (1.3)	0 (0.0)

Data cut-off: January 23, 2020; PP, pemetrexed + platinum; TEAE, treatment-emergent adverse event; TIS, tislelizumab TRAE, treatment-related adverse event

Table 4. TRAEs (≥ 20%) in patients who were smokers or non-smokers (safety analysis set)

	Smokers			Non-smokers				
Preferred term, n (%)	Arm A TIS + PP (n=146)		Arm B PP (n=66)		Arm A TIS + PP (n=76)		Arm B PP (n=44)	
	Grades 1-2	≥ Grade 3	Grades 1-2	≥ Grade 3	Grades 1–2	≥ Grade 3	Grades 1-2	≥ Grade 3
Patients with ≥ 1 event	145 (99.3)	90 (61.6)	64 (97.0)	30 (45.5)	76 (100.0)	50 (65.8)	43 (97.7)	20 (45.5)
Anemia'	97 (66.4)	24 (16.4)	44 (66.7)	7 (10.6)	54 (71.1)	6 (7.9)	27 (61.4)	4 (9.1)
Leukopenia [†]	86 (58.9)	34 (23.3)	38 (57.6)	9 (13.6)	49 (64.5)	14 (18.4)	27 (61.4)	7 (15.9)
Thrombocytopenia [‡]	67 (45.9)	32 (21.9)	28 (42.4)	9 (13.6)	45 (59.2)	11 (14.5)	27 (61.4)	6 (13.6)
Alanine aminotransferase increased	63 (43.2)	3 (2.1)	20 (30.3)	2 (3.0)	29 (38.2)	5 (6.6)	25 (56.8)	1 (2.3)
Neutropenia	61 (41.8)	60 (41.1)	25 (37.9)	24 (36.4)	22 (28.9)	39 (51.3)	17 (38.6)	15 (34.1)
Nausea	55 (37.7)	1 (0.7)	23 (34.8)	1 (1.5)	39 (51.3)	0 (0.0)	20 (45.5)	0 (0.0)
Aspartate aminotransferase increased	53 (36.3)	1 (0.7)	24 (36.4)	0 (0.0)	33 (43.4)	3 (3.9)	25 (56.8)	0 (0.0)
Decreased appetite	45 (30.8)	2 (1.4)	18 (27.3)	1 (1.5)	18 (23.7)	1 (1.3)	10 (22.7)	0 (0.0)
Fatigue	45 (30.8)	3 (2.1)	18 (27.3)	1 (1.5)	29 (38.2)	0 (0.0)	17 (38.6)	0 (0.0)
Vomiting	30 (20.5)	1 (0.7)	11 (16.7)	1 (1.5)	25 (32.9)	0 (0.0)	12 (27.3)	0 (0.0)

Date out-off. January 23, 2020, "Anemia included: reports of anemia, hemoglobin decreased, and red bobo cell count decreased. L'eukaponia includer leports of uhiles blood ell count decreased and leukaponia Thromotopylopenia includet reports of jatelet count decreased and thromotoptopenia. Neutropenia included: reports of neutrophi count decreased and eukopenia. "Faligue included sathenia, faligue, and malaise, PP, pemetevec 4 palitimum," Til Statistumab: Trade, trade-termine-telled adverse event

References

- 1. Walser T, et al. Proc Am Thorac Soc. 2008;5(8):811–5 2. Youlden DR. Cramb SM. Baade PD. J Thorac Oncol. 2008;3(8):819–31
- Foulder DR, Cramb SM, Baade PD: 3 Thorac Oricol. 2008;3(6):81
 Feng Y et al. Cancer Res. 2019;79(13 suppl):2383
- Zhang T, et al. Cancer Immunol Immunother 2018;67(7):1079–90 5 Lu S, et al. J. Thorac Oncol 2021;16(9):1512–1522

Acknowledgements

This study is sponsored by BeiGene, Ltd. Medical writing support, under the direction of the authors, was provided by Cymthia Li, PhD, and Tamsin Grewal, MSc, of Ashfield MedComms, an Ashfield Health company, and was funded by BeiGene Itd.

Author contact details: shun_lu@hotmail.com (Shun Lu)